AEterna Zentaris Inc (AEZS)

3.67
0.00 (0.00)
NASDAQ : Health Care
Prev Close 3.67
Open 3.67
Day Low/High 3.61 / 3.72
52 Wk Low/High 2.60 / 15.70
Volume 64.53K
Avg Volume 179.10K
Exchange NASDAQ
Shares Outstanding 9.94M
Market Cap 36.58M
EPS -18.10
P/E Ratio 0.47
Div & Yield N.A. (N.A)

Latest News

Aeterna Zentaris And Rafa Laboratories Sign Exclusive License Agreement For Zoptrex™ In Israel

Aeterna Zentaris And Rafa Laboratories Sign Exclusive License Agreement For Zoptrex™ In Israel

Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZ) (the "Company") and Rafa Laboratories, Ltd.

Aeterna Zentaris To Announce Second Quarter 2016 Financial And Operating Results On August 9, 2016

Aeterna Zentaris To Announce Second Quarter 2016 Financial And Operating Results On August 9, 2016

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") will announce its second quarter 2016 financial and operating results after market close on Tuesday, August 9, 2016.

Aeterna Zentaris And Orient EuroPharma Co., Ltd. Sign Exclusive License Agreement For Zoptrex™ In Taiwan And Southeast Asia

Aeterna Zentaris And Orient EuroPharma Co., Ltd. Sign Exclusive License Agreement For Zoptrex™ In Taiwan And Southeast Asia

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") and Orient EuroPharma Co.

Aeterna Zentaris Announces IND Submission By Sinopharm A-Think

Aeterna Zentaris Announces IND Submission By Sinopharm A-Think

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its licensee, Sinopharm A-Think Pharmaceuticals Co.

Aeterna Zentaris Reconfirms Commitment To LHRH-receptor Targeting Zoptrex™ During 2016 ASCO Annual Meeting

Aeterna Zentaris Reconfirms Commitment To LHRH-receptor Targeting Zoptrex™ During 2016 ASCO Annual Meeting

Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company") today reconfirmed its commitment to LHRH-receptor targeted therapy and its expectation that the pivotal, phase 3 trial for Zoptrex™ (zoptarelin...

Aeterna Zentaris Elects Ms. Carolyn Egbert As Independent Chair Of The Board

Aeterna Zentaris Elects Ms. Carolyn Egbert As Independent Chair Of The Board

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health, today...

Aeterna Zentaris Announces Election Of Directors At 2016 Shareholders' Meeting

Aeterna Zentaris Announces Election Of Directors At 2016 Shareholders' Meeting

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health, today...

Aeterna Zentaris Reports First Quarter 2016 Financial And Operating Results

Aeterna Zentaris Reports First Quarter 2016 Financial And Operating Results

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health, today reported...

Aeterna Zentaris Acquires Exclusive U.S. Promotional Rights For APIFINY® Prostate Cancer Blood Test

Aeterna Zentaris Acquires Exclusive U.S. Promotional Rights For APIFINY® Prostate Cancer Blood Test

Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company") today announced that, effective as of June 1, 2016, it has acquired the exclusive right to promote APIFINY ®, the only cancer specific, non-PSA blood test...

Aeterna Zentaris To Announce First Quarter 2016 Financial And Operating Results On May 9, 2016

Aeterna Zentaris To Announce First Quarter 2016 Financial And Operating Results On May 9, 2016

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") will announce its first quarter 2016 financial and operating results after market close on Monday, May 9, 2016.

Aeterna Zentaris Mails Information Circular In Connection With Annual Meeting Of Shareholders

Aeterna Zentaris Mails Information Circular In Connection With Annual Meeting Of Shareholders

Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) ("Aeterna Zentaris" or the "Company") today announced that it has mailed a Notice of Meeting and Management Information Circular (the "Meeting Materials") to the shareholders...

Aeterna Zentaris Announces At The Market Issuance Program

Aeterna Zentaris Announces At The Market Issuance Program

Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company") announced today that it has entered into an At Market Issuance ("ATM") Sales Agreement, dated April 1, 2016, with H.

Aeterna Zentaris Reports Fourth Quarter And Full-Year 2015 Financial And Operating Results

Aeterna Zentaris Reports Fourth Quarter And Full-Year 2015 Financial And Operating Results

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health, today reported...

Aeterna Zentaris To Announce Fourth Quarter And Full-Year 2015 Financial And Operating Results On March 29, 2016

Aeterna Zentaris To Announce Fourth Quarter And Full-Year 2015 Financial And Operating Results On March 29, 2016

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") will announce its fourth quarter and full-year 2015 financial and operating results after market close on Tuesday, March 29, 2016.

Aeterna Zentaris Reports On Zoptrex™ Development Progress In China

Aeterna Zentaris Reports On Zoptrex™ Development Progress In China

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its licensee, Sinopharm A-Think Pharmaceuticals Co.

Company Profile For Aeterna Zentaris Inc.

Company Profile For Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health.

Aeterna Zentaris Commences Promotional Activities For APIFINY® Prostate Cancer Blood Test

Aeterna Zentaris Commences Promotional Activities For APIFINY® Prostate Cancer Blood Test

Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company") today announced that it has started promoting APIFINY ®, the only cancer specific, non-PSA blood test for the evaluation of the risk of prostate cancer, in...

Aeterna Zentaris Appoints Geneviève Lemaire As Vice President, Finance And Chief Accounting Officer

Aeterna Zentaris Appoints Geneviève Lemaire As Vice President, Finance And Chief Accounting Officer

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the appointment of Ms.

Aeterna Zentaris To Participate In 18th Annual BIO CEO & Investor Conference Seeking Partnering Opportunities

Aeterna Zentaris To Participate In 18th Annual BIO CEO & Investor Conference Seeking Partnering Opportunities

Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company") today announced that Chairman, President and Chief Executive Officer David A.

Aeterna Zentaris Announces Appointments To Board Of Directors

Aeterna Zentaris Announces Appointments To Board Of Directors

Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company") today announced the appointment of Michael Cardiff and Ken Newport to its Board of Directors, effective immediately, for a term to expire at the Company's...

Aeterna Zentaris Files International Patent Application For Novel Method Of Manufacturing Zoptrex™

Aeterna Zentaris Files International Patent Application For Novel Method Of Manufacturing Zoptrex™

Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company") today announced that it has filed an international patent application as well as national patent applications in selected countries including the US, China,...

Strong On High Volume: AEterna Zentaris (AEZS)

Strong On High Volume: AEterna Zentaris (AEZS)

Trade-Ideas LLC identified AEterna Zentaris (AEZS) as a strong on high relative volume candidate

Aeterna Zentaris Announces Additional Market Purchases Of Common Shares By Executive Management

Aeterna Zentaris Announces Additional Market Purchases Of Common Shares By Executive Management

Aeterna Zentaris Inc. (NASDAQ:AEZS; TSX:AEZ) (the "Company") today disclosed that it was advised by certain members of its executive management team that such executives made on-market purchases of an aggregate of 29,535 of...

Aeterna Zentaris Concludes Successful Meeting Of Clinical Investigators For Confirmatory Phase 3 Trial Of Macrilen™

Aeterna Zentaris Concludes Successful Meeting Of Clinical Investigators For Confirmatory Phase 3 Trial Of Macrilen™

Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company") announced today that it concluded a successful meeting of the clinical investigators for the confirmatory Phase 3 trial of Macrilen™ (macimorelin), a...

Aeterna Zentaris Affirms Focus On Targeted Oncology During 2016 J.P. Morgan Healthcare Conference

Aeterna Zentaris Affirms Focus On Targeted Oncology During 2016 J.P. Morgan Healthcare Conference

Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company") today affirmed its focus on targeted oncologic therapies during the 2016 J.

Aeterna Zentaris Announces Filing Of Preliminary Base Shelf Prospectus

Aeterna Zentaris Announces Filing Of Preliminary Base Shelf Prospectus

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that it has filed a preliminary short form base shelf prospectus (the "Shelf Prospectus") with the securities regulatory authorities in each of...

Aeterna Zentaris Announces Closing Of US$16.65 Million Public Offering Of Common Shares And Warrants

Aeterna Zentaris Announces Closing Of US$16.65 Million Public Offering Of Common Shares And Warrants

Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company") today announced the closing of its previously announced underwritten public offering (the "Offering") of 3.

Aeterna Zentaris Announces Pricing Of US$16.65 Million Public Offering Of Common Shares And Warrants

Aeterna Zentaris Announces Pricing Of US$16.65 Million Public Offering Of Common Shares And Warrants

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZ) (the "Company") today announced the pricing of its previously announced underwritten public offering (the "Offering") of common shares and warrants with a public offering...